Eculizumab is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor.In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death.Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
中文别名:
依库珠单抗
英文别名:
h5G1.1; h5G1.1VHC+h5G1.1VLC; Eculizumab; Soliris; ZINC65731199; D08IXA; AC1MIWQ3